David A. B. Smith
University of Pennsylvania · 35 works · 2,846 citations · h-index 13
Top works
- Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine
- Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
- New storage procedure for human tumor biopsies prior to estrogen receptor measurement.
- Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs docetaxel in 2L/3L NSCLC (POPLAR).
- A Biomechanical Study of Regional Endplate Strength and Cage Morphology as It Relates to Structural Interbody Support
- Central Quadriceps Tendon for Anterior Cruciate Ligament Reconstruction
- Immunocytochemistry of cerebellar astrocytomas: with a special note on rosenthal fibres
- Breast cancer cell-free DNA (cfDNA) profiles reflect underlying tumor biology: The Circulating Cell-Free Genome Atlas (CCGA) study.
- Pemetrexed in Relapsed Small-Cell Lung Cancer and the Impact of Shortened Vitamin Supplementation Lead-In Time: Results of a Phase II Trial
- Histologic Characterization of Acute Spinal Cord Injury Treated with Intravenous Methylprednisolone
- An Open-label, Single-arm, Phase 2 Trial of Panitumumab Plus FOLFIRI as Second-line Therapy in Patients with Metastatic Colorectal Cancer
- A phase 1 study of MM-111, a bispecific HER2/HER3 antibody fusion protein, combined with multiple treatment regimens in patients with advanced HER2-positive solid tumors.
- A five-arm, open-label, phase I/lb study to assess safety and tolerability of the oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with chemotherapy or erlotinib in patients with advanced solid tumors.
- Evaluation of Urinary Incontinence
- A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma
- Phase II trial of panobinostat (LBH589) in patients (pts) with refractory metastatic colorectal cancer (MCRC).
- A first-in-man phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody OMP-305B83 in patients with previously treated solid tumors
- An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors
- Interference in Urea Determination by High Immunoglobulin Levels
- Genomic mutation profiling (GMP) and clinical outcome of patients treated with buparlisib (PI3K inhibitor) in the “Signature” program.